Condition: Head and Neck Cancer · Oropharynx Cancer · Human Papilloma Virus · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.
This description comes directly from the study's public registry record.
Diane Trudel · 514-890-8254 · diane.dt.chum@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| London Health Sciences Center | London, Ontario, Canada | Recruiting |
| Centre Hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04178174